Automation and validation of a rapid method to assess neutrophil and monocyte activation by routine fluorescence flow cytometry in vitro

Cytometry Part B - Clinical Cytometry

Volumn 74, Issue 5, 2008, Pages 295-309

  Linssen, J ^a   Aderhold, S ^b   Nierhaus, A ^c   Frings, D ^c   Kaltschmidt, C ^a   Zanker K ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b SYSMEX CORPORATION   (Japan)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Automated rapid method; Ex vivo LPS or fMLP stimulation; ICU patients; Innate immune activation; Sysmex XE2100

Indexed keywords

EDETIC ACID; HLA DR ANTIGEN; INTERLEUKIN 8; LIPID; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; NUCLEIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOMATION; BLOOD ANALYSIS; CELL ACTIVITY; CELL SHAPE; CELL VOLUME; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE ANALYSIS; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; LEUKOCYTE ACTIVATION; LIPID MEMBRANE; MALE; MEMBRANE COMPONENT; METHODOLOGY; MONOCYTE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; SCHOOL CHILD; SCREENING TEST; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; AUTOMATION; CELL SHAPE; CHILD; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HEALTH; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-8; KINETICS; LIPOPOLYSACCHARIDES; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; NEUTROPHIL ACTIVATION; NEUTROPHILS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 51749111590     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20422     Document Type: Article

References (41)

1. Song WC, Sarrias MR, Lambris JD. Complement and innate immunity. Immunopharmacology 2000;49:187-198.
2. van Furth R, Diesselhoff-den Dulk MM, Mattie H. Quantitative study on the production and kinetics of mononuclear pbagocytes during an acute inflammatory reaction. J Exp Med 1973;138:1314-1330.
3. Bennouna S, Bliss SK, Curiel TJ, Denkers EY. Cross-tatk in the innate immune system: Neutrophils instruct recruitment and activation of dendritic cells during microbial infection. J Immunol 2003;171: 6052-6058.
4. Wittamer V, Bondue B, Guillabert A, Vassart G, Parmentier M, Communi D. Neutrophil-mediated maturation of chemerin: A link between innate and adaptive immunity. J Immunol 2005;175:487-493.
5. Scapini P Carletto A, Nardelli B, Calzetti F, Roschke V, Merigo F, Tamassia N, Pieropan S, Biasi D, Sbarbati A, Sozzani S, Bambara L, Cassatella M. Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: Implications for inflammatory diseases. Blood 2005;105:830-837.
6. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001;61:4756-4760.
7. Stark MA, Huo Y, Burcin, TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 2005;22:285-294.
8. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L. Conversion of proepithelin to epithelins: Roles of SLP1 and elastase in host defense and wound repair. Cell 2002;111:867-878.
9. Klebanoff SJ. Myeloperoxidase: Friend and foe. J Leukoc Biol 2005; 77:598-625.
10. Sachse C, Prigge M, Cramer G, Pallua N, Henkel E. Association between reduced human leukocyte antigen (HLA-DR) expression on blood monocytes and increased plasma level of interleukin-10 in patients with severe burns. Clin Chem Lab Med 1999;37:193-198.
11. Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, Trentz O Schildberg FW. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995;85:1341-1347.
12. Munoz C, Carlet J, Fitting C, Misset B, Blériot JP Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991;88:1747-1754.
13. Marie C, Muret J, Fitting C, Losser M-R, Payen D, Cavaillon J-M. Reduced ex vivo interleukin-8 production by neutrophils in septic and nonseptic systemic inflammatory response syndrome. Blood 1998; 91:3439-3446.
14. Davis BH, Olsen SH, Ahmad E, Bigelow NC. Neutrophil CD64 is an improved indicator of infection or sepsis in emergency department patients. Arch Pathol Lab Med 2006;130:654-661.
15. Livaditi O, Kotanidou A, Psarra A, Dimopolou I, Sotiropoulou C, Augustatou K, Papasteriades C, Armaganidis A, Roussos C, Orfanos SE, Douzinas EE. Neutrophil CD64 expression and serum IL-8: Sensitive early markers of severity and outcome in sepsis. Cytokine 2006;36:283-290.
16. van der Meer W, Pickkers P, Scott CS, van der Hoeven JG, Gunnewick JK. Hematological indices, inflammatory markers and neutrophil CD64 expression: Comparative trends during experimental human endotoxemia. J Endotoxin Res 2007;13:94-100.
17. Briggs C, Kunka S, Fujimoto H, Hamaguchi Y, Davis BH, Machin SJ. Evaluation of immature granulocyte counts by the XE-IG master: Upgraded software for the XE-2100 automated hematology analyzer. Lab Hematol 2003;9:117-124.
18. Nigro KG, O'Riordan M, Molloy EJ, Walsh MC, Sandhaus LM. Performance of an automated immature granulocyte count as a predictor of neonatal sepsis. Am J Clin Pathol 2005;123:618-624.
19. Epling CL, Stites DP, McHugh TM, Chong HO, Blackwood LL, Wara DW. Neutrophil function screening in patients with chronic granulomatous disease by a flow cytometric method. Cytometry 1992;13: 615-620.
20. Kuijpers TW, van Lier RAW, Hamann D, de Boer M, Thung LY, Weening RS, Verhoeven AJ, Roos D. Leukocyte adhesion deficiency type 1 (LAD-1)/ variant. J Clin Invest 1997;100:1725-1733.
21. Ottonello L, Dapino P, Pastorino G, Dallegri F, Saccetti C. Neutrophil dysfunction and increase susceptibility to infection. Eur J Clin Invest 1995;25:687-692.
22. DeMeo AN, Anderson BR. Defective chemotaxis associated with a serum inhibitor in cirrhotic patients. N Engl J Med 1972;286:735-740.
23. Review. David yocum effective use of TNF antagonists. Arthritis Res Ther 2004;6 (Suppl 2):24-30.
24. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-867.
25. Stamminger G, Performance of the XE-2100 leucocyte differential. Clin Lab Haem 2002;24:271-280.
26. Ishii T, Kawasumi I, Matsumoto H. IMI channel-focusing on the roles and functions of surfactant. Sysmex J Int 1997;7:123-128.
27. Swolin B, Simonsson P, Backman S, Lofqvist I, Bredin I, Johnsson M. Differential counting of blood leukocytes using automated microscopy and a decision support system based on artificial neural networks, evaluation of DiffMaster (DM). Clin Lab Haem 2003;25:139-147.
28. van Pelt J, Huisman MV, Weening RS, von dem Borne AEGKr, Roos D, van Oers RHJ. A single dose of granulocyte-macrophage colony-stimulating factor induces systemic interleukin-8 release and neutrophil activation in healthy volunteers. Blood 1996;87:5305-5313.
29. Sham RL, Phatak PD, Ihne TP, Abboud CN, Packman CH. Signal pathway regulation of interleukin-8-induced actin polymerization in neutrophils. Blood 1993;82:2546-2551.
30. Sengelov H, Kjeldsen L, Borregaard N. Control of exocytosis in early neutrophil activation. J Immunol 1993;150:1535-1543.
31. Videm V, Ødegard A, Myhre HO. Iohexol-induced neutrophil myeloperoxidase release and activation upon contact with vascular stent-graft. J Endovasc Ther 2003;10:958-967.
32. Han H, Fuortes M, Nathan C. Critical role of the carboxyl terminus of proline-rich tyrosine kinase (Pyk2) in the activation of human neutrophils by tumour necrosis factor: Separation of signals for the respiratory burst and degranulation. J Exp Med 2003;197:63-75.
33. Thelen M, Peveri P, Kernen P, von Tschamer V, Walz A, Baggiolini M. Mechanism of neutrophil activation by NAF, a novel monocyte-derived peptide agonist. FASEB J 1988;2:2702-2708.
34. 2-. J Biochem 2002; 131:285-292.
35. Bulger EM, Maier RV. Lipidmediators in the pathophysiology of critical illness. Crit Care Med 2000;28:N36.
36. Behre G, Schedel I, Nentwig B, Wormann B, Essink M, Hiddemann W. Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: Correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin m-enriched immunoglobulins. Antimicrob Agents Chemother 1992;36:2139-2146.
37. Marshall JC, Walker PM, Foster DM, Harris D, Ribeiro, M, Paice J, Romaschin AD, Derzko AN. Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Critical Care 2002;6:342-348.
38. Matic M, Simon SR. Tumor necrosis factor release from lipopolysaccharide-stimulated human monocy-tes: lipopolysaccharide tolerance in vivo. Cytokine 1991;3:576-583.
39. Schultz MJ, Olszyna DP, de Jonge E, Verbon A, van Deventer SJH, van der Poll T. Reduced ex vivo chemokine production by polymorphonuclear cells after in vivo exposure of normal humans to endotoxin. J Infect Dis 2000;182:1264-1267.
40. Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Choy EH, Isenberg DA. Efficacy of a novel PEGylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid arthritis. Rheumatology 2000;39:87.
41. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC. Systemic anti-tumor necrosis factor-átherapy in rheumatoid arthritis down-regulates synovial tumor-necrosis factor-á synthesis. Arthritis Rheum 2000;43:2391-2396.